+Vote!
Business Wire (Free subscription) | yesterday
SEATTLE--(BUSINESS WIRE)--ZymoGenetics, Inc. (NASDAQ: ZGEN) announced today that Douglas E. Williams, Ph.D., Chief Executive Officer of ZymoGenetics, will provide an update on company activities at the Piper Jaffray Healthcare Conference in New York City on Wednesday, December 2, 2009 at 8:30 a.m. Eastern Time. A live webcast of the presentation can be accessed by going to: www.zymogenetics.com. The...
+Vote!
The Puget Sound Business Journal (Free subscription) | 23/11/2009
Bruce Carter, who headed Seattle biotech ZymoGenetics Inc. from 1998 to January of this year, has been named executive chairman and director of Immune Design Corp. (ZGEN)
3Vote!
Xconomy (Free subscription) | 23/11/2009
One of Seattle’s leading life sciences entrepreneurs, Bruce Carter, is back in the saddle. Carter has agreed to take an active management role as executive chairman of Seattle-based Immune Design, a year after he announced he was retiring as CEO of ZymoGenetics (NASDAQ: ZGEN). Carter has agreed to work about three days a week at the [...]
3Vote!
PR News Wire (Free subscription) | 23/11/2009
SEATTLE, Nov. 23 /PRNewswire/ -- Immune Design Corp. (IDC) announced today that Dr. Bruce L.A. Carter has joined IDC as Executive Chairman. Dr. Carter has a successful track record in biotechnology executive management. He was the former Chief Executive Officer at ZymoGenetics, in Seattle, WA and Chief Scientific Officer at Novo Nordisk, Copenhagen, Denmark.
3Vote!
StreetInsider.com News Articles (Free subscription) | 19/11/2009
Notable 52-week Highs on the NYSE: Cardinal Health, Inc. (NYSE: CAH) - Hit $31.77. UBS initiated coverage with a Buy rating on Cardinal. Donaldson Company Inc. (NYSE: DCI) - touched $45.09. The company reported Q110 earnings about the Street estimates today. IMS Health Inc. (NYSE: RX) - reached $21.65 King Pharmaceuticals Inc. (NYSE: KG) - hit $11.88. May be benefitting from mixed ZymoGenetics ratings...
Explore : Biotechnologies,
Cardinal Health,
Donaldson Company,
Drug Manufacturers,
Environment,
Financial Services,
Health Care Services,
Health Industries,
IMS Health Inc.,
King Pharmaceuticals,
Merck,
Money,
New York Stock Exchange,
NYSE Group,
Software,
Software and services,
Stock exchange
3Vote!
Stockpreacher Penny Stock Blog (Free subscription) | 12/11/2009
ZymoGenetics Inc. (Nasdaq: ZGEN) ZymoGenetics Inc. (ZGEN) is a biopharmaceutical company, focuses on the discovery, development, manufacture and commercialization of therapeutic proteins for the treatment of human diseases, including hemostasis, inflammatory and autoimmune diseases, cancer and viral infections. Its products include RECOTHROM, a recombinant thrombin, which is a topical hemostatic agent...
3Vote!
Xconomy (Free subscription) | 09/11/2009
ZymoGenetics started really playing hardball with King Pharmaceuticals in August, and now a high-and-tight fastball has come right back at the Seattle biotech company. The projectile in question is a lawsuit filed on November 2 by Bristol, TN-based King in the U.S. District Court in Eastern Tennessee; the suit accuses ZymoGenetics of false advertising, unfair competition, [...]
3Vote!
Seattle Times (Free subscription) | 07/11/2009
A federal court judge in Tennessee has lifted temporary restraining orders that barred ZymoGenetics from making certain claims in its marketing of the blood-clotting agent Recothrom, the Seattle-based biotechnology company said Friday.
3Vote!
bizjournals (Free subscription) | 06/11/2009
ZymoGenetics Inc. said Friday that a federal judge in Tennessee has removed three temporary restraining orders imposed on the company over marketing and promotion of its lead drug, Recothrom. (ZGEN)
3Vote!
Stock Market Analysis (Free subscription) | 06/11/2009
Today, November 6, 2009, there are several stock gainers that are breaking out with some nice momentum. If you are looking to day trade today, you might want to check out the following stocks. Check out some of today's biggest gainers and the Top Stocks for 2009 . You can find my Past, Current, and Future Stock Gainers Report Right Here Top Stocks 11/6/09 - Biggest Gainers Today Discuss Stocks - www.stockstobuy.org...
Explore : Auto industry,
Auto Parts,
Biotechnologies,
Computer industry,
Conglomerates,
Diversified Industrials,
Economy,
Electronics,
Financial Services,
General Electric,
General Electric Co.,
International Game Technology,
KKR Financial,
Magna International,
Markets,
MGIC Investment,
Money,
NVIDIA,
Semi-Conductors,
Stock markets,
Stocks
3Vote!
Seattle Times (Free subscription) | 06/11/2009
ZymoGenetics said its third-quarter loss narrowed substantially as it pared expenses by 20 percent from the same period last year and increased revenue from research collaborations.
3Vote!
GuruFocus Updates (Free subscription) | 05/11/2009
By 10qk. ZymoGenetics Inc. ( ZGEN ) filed Quarterly Report for the period ended 2009-09-30. Read more » »
3Vote!
The Puget Sound Business Journal (Free subscription) | 05/11/2009
ZymoGenetics Inc. said it narrowed its third-quarter net loss to $11.4 million, or 17 cents a share, from a loss of $28.8 million, or 42 cents a share the same quarter a year ago. (ZGEN)
3Vote!
Business Wire (Free subscription) | 05/11/2009
SEATTLE--(BUSINESS WIRE)--ZymoGenetics, Inc. (NASDAQ:ZGEN) today reported improved financial results for the third quarter ended September 30, 2009. The company’s net loss for the quarter declined substantially to $11.4 million, or $0.17 per share, from $28.8 million, or $0.42 per share, for the third quarter of 2008. Revenues for the third quarter of 2009 increased by 131% compared to the third...
3Vote!
Seattle Trademark Lawyer (Free subscription) | 05/11/2009
On Nov. 2, King Pharmaceuticals, Inc. , Monarch Pharmaceuticals, Inc., King Pharmaceuticals Research and Development, Inc., and Gentrac, Inc., filed suit against Seattle-based ZymoGenetics, Inc. , in the Eastern District of Tennessee. The complaint alleges a variety of false advertising and trademark infringement claims related to ZymoGenetics’ topical thrombin products. The complaint alleges...
Videos